The University of Alabama at Birmingham has launched two studies of cannabidiol oil, or CBD oil, as a treatment for severe, intractable seizures. The two studies, an adult study at UAB and a pediatric study at Children’s of Alabama, were authorized by the Alabama Legislature in 2014 by legislation known as Carly’s Law.
Rajesh Kana, Ph.D., of the University of Alabama at Birmingham and colleagues are the first to combine three different measures of the brain — anatomy, the connectivity between different brain regions, and levels of a neurochemical — to distinguish people with autism spectrum disorder (ASD) from matched, typically developing peers.
At this time, autism diagnosis is based on behavior. Kana’s multimodal neuroimaging-based classification is a step toward a possible biomarker for autism and possibly diagnosing autism at an early age, perhaps as early as 6 months, when the brain is very plastic and intervention might be more effective.